Bibliographie sur la PCP

Transcription

1

2 Bibliographie sur la PCP Abraham, H.D., A.M. Aldridge et P. Gogia. The psychopharmacology of hallucinogens, Neuropsycopharmacology, vol. 14, 1996, p Abramson, H.A., M. Jarvik, M. Kaufman, C. Kornestsky, A. Levine et M. Wagner. Lysergic acid diethylamide (LSD-25): Physiological and perceptual responses, Journal of Physiology, vol. 39, 1955, p Barrett, S.P., C. Darredeau et R.O. Pihl. Patterns of simultaneous polysubstance use in drug using university students, Human Psychopharmacology, vol. 21, 2006, p Beach, H.J. Listening for the logos: A study of reports of audible voices at high doses of psilocybin, Dissertation Abstracts International: Section B. The Sciences and Engineering, vol. 57, 1997, p Boutros, N.N. et M.B. Bowers. Chronic substance-induced psychotic disorders: State of the literature, Journal of Neuropsychiatry and Clinical Neurosciences, vol. 8, 1996, p Carter, O.L., F. Hasler, J.D. Pettigrew, G.M. Wallis, G.B. Liu et F. Vollenweider. Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans, Psychopharmacology, vol. 195, 2007, p Carter, O.L., J.D. Pettigrew, D.C. Burr, D. Alais, F. Hasler et F. Vollenweider. Psilocybin impairs high-level but not low-level motion perception, NeuroReport, vol. 15, 2004, p Cerletti, A. Pharmacology of psilocybin. Article présenté lors de la première réunion internationale de neuropsychopharmacologie, Rome, septembre Cité par Isbell, H. Comparison of the reactions induced by psilocybin and LSD-25 in man, Psychopharmacology, vol. 1, 1959, p Cohen, S. Lysergic acid: Side effects and complications, Journal of Nervous and Mental Disease, vol. 130, 1960, p Coordination Centre for the Assessment and Monitoring of New Drugs. Risk assessment report relating to paddos (psilocin and psilocybin), La Haye (Pays-Bas), 2000, Coordination Centre for the Assessment and Monitoring of New Drugs. Cité par Riley, S. et G. Blackman. Between prohibitions: Patterns and meanings of magic mushroom use in the UK, Substance Use and Misuse, vol. 43, 2008, p Centre canadien de lutte contre l alcoolisme et les toxicomanies Mars 2012 Page 2 de 6

3 Creese, I., D.R. Burt et S.H. Snyder. The dopamine receptor: Differential binding of d-lsd and related agents to agonist and antagonist states, Life Science, vol. 17, 1975, p Delgado, P.L. et F.A. Moreno. Hallucinogens, serotin and obsessive compulsive disorder, Journal of Psychoactive Drugs, vol. 30, 1998, p Dobin, R. Dr. Leary s Concord Prison Experiment: A 34-year follow-up study, Journal of Psychoactive Drugs, vol. 30, 1998, p Doblin, R. Pahnke s Good Friday Experiment : A long-term follow-up and methodological critique, Journal of Transpersonal Psychology, vol. 23, 1991, p Erowid. Psilocybin mushrooms, Consulté sur le Espiard, M.L., L. Lecardeur, P. Abadie, I. Halbecq et S. Dolfus. Hallucinogen persisting perception disorder after psilocybin consumption: A case study, European Psychiatry, vol. 20, 2005, p Gouzoulis-Mayfrank, E., B. Thelen, L. Hermle et H. Sass. History, rationale, and potential of human experimental hallucinogenic drug research in psychiatry, Pharmacopsychiatry, vol. 31, 1998, p Gouzoulis-Mayfrank, E., M. Schreckenberg, O. Sabri, C. Arning, B. Thelen, M. Spitzer, K. Kovar, L. Hermle, U. Büll et H. Sass. Neurometabolic effects of psilocybin, 3,4- Methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers, Neuropsychopharmacology, vol. 20, 1999, p Greenberg, G. Good trips, bad trips: Psychedelic drugs and dissociation. Dans S. Krippner et S.M. Powers (éd.), Broken images, broken selves: Dissociative narratives in clinical practice (p ), Philadelphie, Brunner/Mazel, Griffiths, R.R., W.A. Richards, M.W. Johnson, U. McCann et R. Jesse. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later, Journal of Psychopharmacology, vol. 22, 2008, p Griffiths, R.R., W.A. Richards, U. McCann et R. Jesse. Psilocybin can occasion mysticaltype experiences having substantial and sustained personal meaning and spiritual significance, Psychopharmacology, vol. 187, 2006, p Grob, C.S. Psilocybin research with advanced-stage cancer patient, Multidisciplinary Association for Psychedelic Studies Bulletin, vol. 15(3), 2005, p. 8. Centre canadien de lutte contre l alcoolisme et les toxicomanies Mars 2012 Page 3 de 6

4 Halpern, J.H. et H.G. Pope. Do hallucinogens cause residual neuropsychological toxicity?, Drug and Alcohol Dependence, vol. 53, 1999, p Halpern, J.H. et H.G. Pope. Hallucinogen persisting perception disorder: What do we know after 50 years?, Drug and Alcohol Dependence, vol. 69, 2003, p Hasler, F., U. Grimberg, M.A. Benz, T. Huber et F. Vollenweider. Acute psychological and physiological effects of psilocybin in healthy humans: A double blind, placebocontrolled dose-effect study, Psychopharmacology, vol. 172, 2004, p Hermle L., M. Fünfgeld, G. Oepen, H. Botsch, D. Borchardt, E. Gouzoulis, R.A. Fehrenbach et M. Spitzer. Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects. Experimental psychosis as a tool for psychiatric research, Biological Psychiatry, vol. 32, 1992, p Hofman, A. Chemical aspects of psilocybin; the psychotropic principle from the Mexican fungus, Psilocybe Mexicana, article présenté à la première réunion internationale de neuropsychopharmacologie, Rome, septembre Cité par Isbell, H. Comparison of the reactions induced by psilocybin and LSD-25 in man, Psychopharmacology, vol. 1, 1959, p Holstein, F. Flashbacks: A personal follow-up, Archives of Psychiatry and Neurological Sciences, vol. 222, 1976, p Horgan, J. The Electric Kool-Aid clinical trial, New Scientist, vol. 185, 2005, p Isbell, H. Comparison of the reactions induced by psilocybin and LSD-25 in man, Psychopharmacology, vol. 1, 1959, p Johnson, M.W., W.A. Richards et R.R. Griffiths. Human hallucinogen research: Guidelines for safety, Journal of Psychopharmacology, vol. 22, 2008, p Julien, R.M. A primer of drug action: A concise, nontechnical guide to the actions, uses, and side effects of psychoactive drugs, New York, W.H. Freeman and Company, Keeler, M.H. et C.B. Reifler. Suicide during an LSD reaction, American Journal of Psychiatry, vol. 123, 1967, p Kenna, J.C. et G. Sedman. The subjective experience of time during lysergic acid diethylamide (LSD-25) intoxication, Psychopharmacologia, vol. 5, 1964, p Lerner, A.G., M. Gelkopf, I. Skladman, I. Oyffe, B. Finkel, M. Sigal et A. Weizman. Flashback and hallucinogen persisting perception disorder: Clinical aspects and pharmacological treatment approach, Israel Journal of Psychiatry Relating Science, vol. 29, 2002, p Centre canadien de lutte contre l alcoolisme et les toxicomanies Mars 2012 Page 4 de 6

5 Maisto, S.A., M. Galizio et G.J. Connors. Drug use and abuse, Belmont (CA), Thomson Higher Education, Marsa, L. Acid test, Discover, vol. 29, 2008, p Metzner, R. Teonanacatl: Sacred mushrooms of visions, El Verano (CA), FourTree Press, Moreno, F.A., C.B. Wiegand, E.K. Taitano et P.L. Delgado. Safety, tolerability and efficacy on psilocybin in 9 patients with obsessive-compulsive disorder, Journal of Clinical Psychiatry, vol. 67, 2006, p Pahnke, W. Drugs and mysticism: An analysis of the relationship between psychedelic drugs and the mystical consciousness (thèse de doctorat, Université Harvard), Cité par Doblin, R. Pahnke s Good Friday Experiment : A long-term follow-up and methodological critique, Journal of Transpersonal Psychology, vol. 23, 1991, p Passie, T., J. Seifert, U. Shnierder et M. Hinderk. The pharmacology of psilocybin, Addiction Biology, vol. 7, 2006, p Pierrot, M., P. Josse et M.F. Raspiller. Intoxications par champignons hallucinogènes, Annales de Médecine Interne, vol. 151, 2000, p Pollock, S.H. Liberty caps: Recreational hallucinogenic mushrooms, Drug and Alcohol Dependence, vol. 1, 1975, p Riley, S. et G. Blackman. Between prohibitions: Patterns and meanings of magic mushroom use in the UK, Substance Use and Misuse, vol. 43, 2008, p Schultes, R.E. Hallucinogens of plant origin, Science, vol. 163, 1969, p Schwartz, R.H. et D.E. Smith. Hallucinogenic mushrooms, Clinical Pediatrics, vol. 27, 1988, p Sessa, B. Is it time to revisit the role of psychedelic drugs in enhancing human creativity?, Journal of Psychopharmacology, vol. 22, 2008, p Sewell, A.R., J.H. Hapern et H.G. Pope. Response of cluster headache to psilocybin and LSD, Neurology, vol. 66, 2006, p Siegal, R.K. Fire in the brain: Clinical tales of hallucination, New York, Dutton, Stamets, P. Psilocybin mushrooms of the world: An identification guide, Berkeley (CA), Ten Speed Press, Centre canadien de lutte contre l alcoolisme et les toxicomanies Mars 2012 Page 5 de 6

6 Strassman, R. Adverse reactions to psychedelic drugs: A review of the literature, Journal of Nervous and Mental Disease, vol. 172, 1984, p Vollenwider, F., K.L. Leenders, C. Scharfetter, P. Maguire, O. Stadelman et J. Angst. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis, Neuropsychopharmacology, vol. 16, 1997, p Vollenweider, F., M. Vollenweider-Scherpenhuyzen, A. Bäbler, H. Vogel et D. Hell. Psilocybin induces schizophrenia-like psychosis in humans via a serontonin-2 agonist action, NeuroReport, vol. 9, 1998, p Wackermann, J., M. Wittman, F. Hasler et F. Vollenweider. Effects of varied doses of psilocybin on time interval reproduction in human subjects, Neuroscience Letters, vol. 435, 2008, p Wapner, S. et D.M. Krus. Effects of lysergic acid diethylamide, and differences between normals and schizophrenics on the Stroop Color-Word Test, Journal of Neuropsychiatry, vol. 2, 1960, p Wasson, R.G. The wondrous mushroom: Mycolatry in Mesoamerica, New York, McGraw- Hill Book Co., Wasson, V.P. et R.G. Wasson. Mushrooms, Russia and history, New York, Pantheon Books, Wittman, M., O. Carter, F. Hasler, B.R. Cahn, U. Grimberg, P. Spring, D. Hell, H. Flohr et F. Vollenweider. Effects of psilocybin on time perception and temporal control of behaviour in humans, Journal of Psychopharmacology, vol. 21, 2007, p Wolbach, A.B., E.J. Miner et H. Isbell. Comparison of psilocin with psilocybin, mescaline and LSD-25, Psychopharmacologia, vol. 3, 1962, p Centre canadien de lutte contre l alcoolisme et les toxicomanies 75, rue Albert, bureau 500 Ottawa (Ontario) K1P 5E7 Canada Tél. : Téléc. : info@ccsa.ca Centre canadien de lutte contre l alcoolisme et les toxicomanies Mars 2012 Page 6 de 6